Presentation Type
Oral Presentation
Presentation Type
Submission
Keywords
Obesity, weight loss, tirzepatide, semaglutide
Department
Nutritional Science
Major
Nutritional Science (B.S.)
Abstract
Obesity is a major epidemic across the United States, and weight loss through diet and physical activity alone is not sustainable. Treatment with tirzepatide and semaglutide have proven to be effective for obesity management in the short-term, but more research is needed to understand how certain types of medications impact weight loss over time. In this study, we recruited 42 adult participants with or without Type II diabetes who were 21 years and older, taking only one GLP-1 or GIP/GLP-1 receptor agonist at a time, had a beginning body mass index of 30 or greater or a beginning body mass index of 27 or higher with at least one obesity-related comorbidity. After completing an online Qualtrics survey, a total of 38 participants (N = 38) were retained for analysis. We conducted a paired samples t-test to assess pre- and post-intervention differences, along with an ANOVA test to assess the effectiveness of specific medication types and their dosages. The primary endpoint was percent change in body weight from baseline (mean = -16.16%, SD = 11.29%), and key secondary endpoints included change in BMI (mean = 6.34, SD = 5.01) and change in waist circumference (mean = 6.40 in., SD = 4.12 in.). Nutritional patterns and physical activity status were studied together with these endpoints. Among all participants who were overweight with one obesity-related comorbidity or obese, weight, BMI, and waist circumference were all significantly reduced (p< 0.001).
Faculty Mentor
Dr. Susan Helm
Funding Source or Research Program
Not Identified
Location
Black Family Plaza Classroom 191
Start Date
10-4-2026 2:15 PM
End Date
10-4-2026 2:45 PM
Efficacy of GLP-1 and GIP/GLP-1 Receptor Agonists on the Body Weight Management of Obesity
Black Family Plaza Classroom 191
Obesity is a major epidemic across the United States, and weight loss through diet and physical activity alone is not sustainable. Treatment with tirzepatide and semaglutide have proven to be effective for obesity management in the short-term, but more research is needed to understand how certain types of medications impact weight loss over time. In this study, we recruited 42 adult participants with or without Type II diabetes who were 21 years and older, taking only one GLP-1 or GIP/GLP-1 receptor agonist at a time, had a beginning body mass index of 30 or greater or a beginning body mass index of 27 or higher with at least one obesity-related comorbidity. After completing an online Qualtrics survey, a total of 38 participants (N = 38) were retained for analysis. We conducted a paired samples t-test to assess pre- and post-intervention differences, along with an ANOVA test to assess the effectiveness of specific medication types and their dosages. The primary endpoint was percent change in body weight from baseline (mean = -16.16%, SD = 11.29%), and key secondary endpoints included change in BMI (mean = 6.34, SD = 5.01) and change in waist circumference (mean = 6.40 in., SD = 4.12 in.). Nutritional patterns and physical activity status were studied together with these endpoints. Among all participants who were overweight with one obesity-related comorbidity or obese, weight, BMI, and waist circumference were all significantly reduced (p< 0.001).